Recent study [45] found that bone morphogenetic protein-2 (BMP-2) was negatively correlated with atrial natriuretic peptide (ANP) and endogenous peptide brain natriuretic peptide (BNP) in serum of patients with type 2 diabetes mellitus combined with chronic heart failure, while in vitro experiments demonstrated that BMP-2 could protect myocardium by inhibition of NLRP3 inflammatory vesicles activation and scorching to protect cardiomyocytes, suggesting that BMP-2 may be a new target for the treatment of DCM. This evidence concerns the gene NPPA and familial dilated cardiomyopathy.